| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8816877 | American Journal of Preventive Medicine | 2017 | 10 Pages |
Abstract
In the first comparative effectiveness trial of diabetes prevention treatments, a 12-month ILI produced significantly greater weight loss than metformin and standard care among Latinas with prediabetes. These data suggest that ILI delivered by promotoras is an effective strategy for preventing diabetes in this high-risk group, which may be superior to metformin. Future pragmatic trials involving larger samples should examine differences in diabetes incidence associated with these treatments.
Related Topics
Health Sciences
Medicine and Dentistry
Public Health and Health Policy
Authors
Matthew J. MD, MSc, Alberly BS, Adam B. BS, Victor A. DMD, MPH, MSc, Robert C. MD, MPH, Gary D. PhD, Ronald T. MD, MPH, Jody D. PhD, Carol PhD,